Inhibition of CFU-GM formation by P1218-specific CTLs.

CD34⁺ BMMC/PBMC derived from healthy controls and from patients with CML were cultured in the presence or absence of P1218-specific CTLs at an effector-target ratio of 10:1 before plating in methylcellulose. Means ± SDs of the percentage of CFU-GM after treatment with CTLs are compared with mock-treated control in duplicate plates for 4 HLA A2⁺ and 3 HLA-A2⁻ healthy controls and 5 HLA-A2⁺ patients and 2 HLA-A2⁻patients with CML.